November 14, 2025 / 5E Advanced Materials, Inc. ("5E" or the "Company") (Nasdaq:FEAM)(ASX:5EA), a development stage company ...

Company achieved FDA alignment on Phase 3 Oz-V trial for the treatment of 2L+ OPSCC, which will evaluate dual primary ...

Olympe Imagerie to deploy Nanox.ARC at Paris-area Hospital Privé Jacques Cartier MASSY for lung cancer screening applications ...

The aim is to find new uses of real-world data in AI development, and to help health systems move from fragmented, compliance ...

When people trust you, they follow your work, not your trends. They read your words with intention. They root for your ...

For rare diseases, AI-driven repurposing fills a critical gap. With more than 7000 rare diseases and only a small percentage ...

Given the success of Research Topic <a href=" in Targeted Therapy and Biomarker Research for Endocrine-Related Cancers and ...

PolyPid Ltd. (NASDAQ: PYPD) Q3 2025 Earnings Call Transcript November 12, 2025 PolyPid Ltd. beats earnings expectations.

Site onboarding varies by location due to individual site constraints and policies.

Learn how the European Union’s Corporate Sustainability Reporting Directive (CSRD) is designed to enhance the transparency of ...

Capital raised -- $17.1 million in new funding was secured, including a $13 million post-quarter investment from a leading ...